

Zhanguo Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3636159/publications.pdf>

Version: 2024-02-01

140
papers

8,968
citations

218677

26
h-index

48315

88
g-index

154
all docs

154
docs citations

154
times ranked

11023
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure. <i>Immunity</i> , 2013, 39, 770-781.	14.3	571
4	Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. <i>Nature Medicine</i> , 2016, 22, 991-993.	30.7	457
5	Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 141-149.	0.9	223
6	A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. <i>Nature Genetics</i> , 2017, 49, 433-437.	21.4	143
7	Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 278-285.	0.9	128
8	2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 357-375.	1.9	115
9	<scp>APLAR</scp> rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 685-713.	1.9	109
10	Hypoxia-inducible factor-1 α perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis. <i>European Journal of Immunology</i> , 2016, 46, 742-751.	2.9	66
11	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.9	66
12	Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis. <i>Science Advances</i> , 2022, 8, eabm1511.	10.3	62
13	Profiling the origin, dynamics, and function of traction force in B cell activation. <i>Science Signaling</i> , 2018, 11, .	3.6	59
14	Toll-Like Receptors Expressed by Synovial Fibroblasts Perpetuate Th1 and Th17 Cell Responses in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e100266.	2.5	58
15	Ash1l and Inc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity. <i>Nature Communications</i> , 2017, 8, 15818.	12.8	53
16	Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 417-417.	0.9	50
17	CD4 T-cell transcriptome analysis reveals aberrant regulation of STAT3 and Wnt signaling pathways in rheumatoid arthritis: evidence from a case-control study. <i>Arthritis Research and Therapy</i> , 2015, 17, 76.	3.5	45
18	The aryl hydrocarbon receptor suppresses osteoblast proliferation and differentiation through the activation of the ERK signaling pathway. <i>Toxicology and Applied Pharmacology</i> , 2014, 280, 502-510.	2.8	44

#	ARTICLE	IF	CITATIONS
19	Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity. <i>Clinical and Experimental Immunology</i> , 2021, 205, 119-127.	2.6	42
20	Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKC δ^2 and focal adhesion kinase. <i>ELife</i> , 2017, 6, .	6.0	40
21	Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. <i>Modern Rheumatology</i> , 2017, 27, 1066-1071.	1.8	35
22	Impaired CD27+IgD+ B Cells With Altered Gene Signature in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 626.	4.8	34
23	Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study. <i>Nature Communications</i> , 2020, 11, 1911.	12.8	34
24	The Inhibitory Effect of IFN- β on Protease HTRA1 Expression in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2014, 193, 130-138.	0.8	33
25	Targeting TFH cells in human diseases and vaccination: rationale and practice. <i>Nature Immunology</i> , 2022, 23, 1157-1168.	14.5	33
26	Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission. <i>Frontiers in Medicine</i> , 2020, 7, 85.	2.6	31
27	Impact of the leucocyte immunoglobulin-like receptor A3 (<i>LILRA3</i>) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2070-2075.	0.9	30
28	The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. <i>Clinical Rheumatology</i> , 2017, 36, 35-43.	2.2	30
29	Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 67.	17.1	30
30	The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	2.2	29
31	Pathogenic conversion of regulatory B10 cells into osteoclast-priming cells in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2017, 76, 53-62.	6.5	28
32	An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. <i>Science</i> , 2018, 362, 700-705.	12.6	28
33	LAG3 (CD223) and autoimmunity: Emerging evidence. <i>Journal of Autoimmunity</i> , 2020, 112, 102504.	6.5	28
34	Growth of B Cell Receptor Microclusters Is Regulated by PIP 2 and PIP 3 Equilibrium and Dock2 Recruitment and Activation. <i>Cell Reports</i> , 2017, 21, 2541-2557.	6.4	27
35	Sequencing of the MHC region defines <i>HLA-DQA1</i> as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 773-780.	0.9	27
36	The metabolic hormone leptin promotes the function of TFH cells and supports vaccine responses. <i>Nature Communications</i> , 2021, 12, 3073.	12.8	27

#	ARTICLE	IF	CITATIONS
37	Impairment on the lateral mobility induced by structural changes underlies the functional deficiency of the lupus-associated polymorphism FcγRIIB-T232. <i>Journal of Experimental Medicine</i> , 2016, 213, 2707-2727.	8.5	26
38	Interleukin-2 Deficiency Associated with Renal Impairment in Systemic Lupus Erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 117-124.	1.2	26
39	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , 2021, 17, 11-15.	8.0	25
40	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	1.9	24
41	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	1.9	24
42	Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjögren's syndrome by inducing regulatory T cells. <i>Modern Rheumatology</i> , 2021, 31, 186-196.	1.8	23
43	Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. <i>PLoS Pathogens</i> , 2021, 17, e1009858.	4.7	23
44	Monoclonal gammopathy in rheumatic diseases. <i>Clinical Rheumatology</i> , 2018, 37, 1751-1762.	2.2	22
45	Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. <i>Arthritis Research and Therapy</i> , 2021, 23, 167.	3.5	22
46	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. <i>Clinical Rheumatology</i> , 2018, 37, 597-605.	2.2	21
47	Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren's Syndrome. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	2.2	19
48	Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study. <i>Modern Rheumatology</i> , 2020, 30, 321-326.	1.8	18
49	FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding. <i>ELife</i> , 2019, 8, .	6.0	18
50	The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren's Syndrome. <i>Journal of Immunology Research</i> , 2015, 2015, 1-15.	2.2	17
51	Clinical and serologic features of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: a large-scale cross-sectional study. <i>Clinical Rheumatology</i> , 2015, 34, 1877-1884.	2.2	17
52	"Not at target": prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	3.5	17
53	The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. <i>Rheumatology</i> , 2015, 54, 1478-1487.	1.9	16
54	Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1143-1156.	1.9	16

#	ARTICLE	IF	CITATIONS
55	Disability and health-related quality of life in Chinese patients with rheumatoid arthritis: A cross-sectional study. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1709-1715.	1.9	16
56	Lipopolysaccharide-binding protein is a sensitive disease activity biomarker for rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 233-240.	0.8	16
57	Monocytic MDSCs skew Th17 cells toward a pro-osteoclastogenic phenotype and potentiate bone erosion in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2409-2420.	1.9	14
58	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
59	An era of biological treatment in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 1-3.	2.2	13
60	Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. <i>Clinical Rheumatology</i> , 2019, 38, 1047-1054.	2.2	13
61	Dickkopf-1 perpetuated synovial fibroblast activation and synovial angiogenesis in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4279-4288.	2.2	13
62	A Truncated IL-17RC Peptide Ameliorates Synovitis and Bone Destruction of Arthritic Mice. <i>Advanced Healthcare Materials</i> , 2016, 5, 2911-2921.	7.6	12
63	Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 402-414.	1.9	12
64	Autoimmune diseases in China. <i>Advances in Immunology</i> , 2019, 144, 173-216.	2.2	12
65	Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. <i>Clinical Drug Investigation</i> , 2019, 39, 369-377.	2.2	12
66	Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. <i>Rheumatology</i> , 2021, 60, 767-772.	1.9	12
67	Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study. <i>Rheumatology and Therapy</i> , 2021, 8, 835-847.	2.3	12
68	Contribution of dendritic cell immunoreceptor (DCIR) polymorphisms in susceptibility of systemic lupus erythematosus and primary Sjogren's syndrome. <i>Human Immunology</i> , 2015, 76, 808-811.	2.4	11
69	SHIP-1 Deficiency in AID+ B Cells Leads to the Impaired Function of B10 Cells with Spontaneous Autoimmunity. <i>Journal of Immunology</i> , 2017, 199, 3063-3073.	0.8	11
70	<i>Lycium barbarum</i> Polysaccharide Ameliorates Sjogren's Syndrome in a Murine Model. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2001118.	3.3	11
71	Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100128.	2.9	11
72	Salivary gland ultrasonography in primary Sjogren's syndrome from diagnosis to clinical stratification: a multicentre study. <i>Arthritis Research and Therapy</i> , 2021, 23, 305.	3.5	11

#	ARTICLE	IF	CITATIONS
73	Comparison of three classification criteria of rheumatoid arthritis in an inception early arthritis cohort. <i>Clinical Rheumatology</i> , 2016, 35, 2397-2401.	2.2	10
74	Tissue-Specific Autoantibodies Improve Diagnosis of Primary Sjögren's Syndrome in the Early Stage and Indicate Localized Salivary Injury. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	10
75	Red meat intake is associated with early onset of rheumatoid arthritis: a cross-sectional study. <i>Scientific Reports</i> , 2021, 11, 5681.	3.3	10
76	Comparison of the deep immune profiling of B cell subsets between healthy adults and Sjögren's syndrome. <i>Annals of Medicine</i> , 2022, 54, 472-483.	3.8	10
77	A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF- α and RANKL. <i>International Immunopharmacology</i> , 2014, 20, 370-376.	3.8	9
78	The synaptic recruitment of lipid rafts is dependent on CD19-PI3K module and cytoskeleton remodeling molecules. <i>Journal of Leukocyte Biology</i> , 2015, 98, 223-234.	3.3	9
79	Characteristics of germinal center-like structures in patients with Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 245-251.	1.9	9
80	Circulating immune complexome analysis identified anti-tubulin- α -1c as an inflammation associated autoantibody with promising diagnostic value for Behçet's Disease. <i>PLoS ONE</i> , 2018, 13, e0199047.	2.5	9
81	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	1.9	9
82	The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 474-480.	0.8	9
83	Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 757099.	3.9	9
84	Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2018, 19, 383-392.	1.3	8
85	Investigation of C1-complex regions reveals new C1Q variants associated with protection from systemic lupus erythematosus, and affect its transcript abundance. <i>Scientific Reports</i> , 2018, 8, 8048.	3.3	8
86	Tea Consumption Is Associated with Decreased Disease Activity of Rheumatoid Arthritis in a Real-World, Large-Scale Study. <i>Annals of Nutrition and Metabolism</i> , 2020, 76, 54-61.	1.9	8
87	CD70-mediated CD27 expression downregulation contributed to the regulatory B10 cell impairment in rheumatoid arthritis. <i>Molecular Immunology</i> , 2020, 119, 92-100.	2.2	8
88	Needle biopsy compared with surgical biopsy: pitfalls of small biopsy in histological diagnosis of IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2021, 23, 54.	3.5	8
89	MYSM1/miR-150/FLT3 inhibits B1a cell proliferation. <i>Oncotarget</i> , 2016, 7, 68086-68096.	1.8	8
90	Casein Kinase II exacerbates rheumatoid arthritis via promoting Th1 and Th17 cell inflammatory responses. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1017-1024.	3.4	8

#	ARTICLE	IF	CITATIONS
91	A Novel BlyS Peptibody Down-Regulates B Cell and T Helper Cell Subsets In Vivo and Ameliorates Collagen-Induced Arthritis. <i>Inflammation</i> , 2016, 39, 839-848.	3.8	7
92	Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. <i>Clinical Rheumatology</i> , 2020, 39, 491-497.	2.2	7
93	IL-10 served as an indicator in severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 1233-1235.	5.0	7
94	A Novel Autoantibody Induced by Bacterial Biofilm Conserved Components Aggravates Lupus Nephritis. <i>Frontiers in Immunology</i> , 2021, 12, 656090.	4.8	7
95	Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 15, 100240.	2.9	7
96	Establishment of a decision tree model for diagnosis of early rheumatoid arthritis by proteomic fingerprinting. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 835-841.	1.9	6
97	GITRL is associated with increased autoantibody production in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2195-2202.	2.2	6
98	Increased Mer and Axl receptor tyrosine kinase expression on glomeruli in lupus nephritis. <i>Clinical Rheumatology</i> , 2017, 36, 1063-1070.	2.2	6
99	Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis? Study protocol for a randomised, double-blind, and placebo-controlled trial. <i>Trials</i> , 2020, 21, 795.	1.6	6
100	Nanocage-Based Capture-Detection System for the Clinical Diagnosis of Autoimmune Disease. <i>Small</i> , 2021, 17, 2101655.	10.0	6
101	Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China. <i>Clinical Rheumatology</i> , 2019, 38, 3477-3483.	2.2	5
102	Frequencies of the LILRA3 6.7-kb Deletion Are Highly Differentiated Among Han Chinese Subpopulations and Involved in Ankylosing Spondylitis Predisposition. <i>Frontiers in Genetics</i> , 2019, 10, 869.	2.3	5
103	Serum IgG N-glycans act as novel serum biomarkers of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 705-707.	0.9	5
104	Immune responses after influenza vaccination in patients of primary Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 224-230.	1.9	5
105	Malignancy Risk of Immunoglobulin G4-Related Disease: Evidence from a Large Cohort Multicenter Retrospective Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1207-1221.	2.3	5
106	Interleukin 17E associates with haematologic involvement and autoantibody production in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 378-384.	0.8	5
107	A randomized multicenter clinical trial of ⁹⁹ Tc-methylene diphosphonate in treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 161-169.	1.9	4
108	An integrated proteomic and glycoproteomic study for differences on glycosylation occupancy in rheumatoid arthritis. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1331-1338.	3.7	4

#	ARTICLE	IF	CITATIONS
109	Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2. <i>Dermatology and Therapy</i> , 2020, 10, 1181-1184.	3.0	4
110	Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 732-741.	0.8	4
111	Evaluation of soluble CD25 as a clinical and autoimmune biomarker in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 142-149.	0.8	4
112	Designation of a Novel DKK1 Multi-epitope DNA Vaccine and Inhibition of Bone Loss in Collagen-Induced Arthritic Mice. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	3
113	The rise of IL-2 therapy – a picture beyond Treg cells. <i>Nature Reviews Rheumatology</i> , 2017, 13, 386-386.	8.0	3
114	A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. <i>International Immunopharmacology</i> , 2019, 75, 105807.	3.8	3
115	Pulse corticosteroids in treatment of rheumatic disease concomitant with cytomegalovirus infection. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 583-591.	1.9	3
116	Elevating the role of carers in rheumatoid arthritis management in the Asia-Pacific region. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 898-910.	1.9	3
117	Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	2.7	3
118	Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2Âmg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2021, 8, 987-1001.	2.3	3
119	Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 227-234.	0.8	3
120	Interleukin 17E associates with haematologic involvement and autoantibody production in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 378-384.	0.8	3
121	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. <i>Rheumatology</i> , 2022, 61, 4962-4974.	1.9	3
122	Engineering and characterization of a humanized antibody targeting TNF-Î± and RANKL. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 717-722.	2.1	2
123	Barriers to Reconstructive Hand Surgery for Rheumatoid Arthritis in China: A Multicenter Survey of Patients and Physicians. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016, 4, e1126.	0.6	2
124	Genetic markers and clinical relevance in rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 109-113.	1.9	2
125	Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNF-Î± fusion protein, in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1095-1101.	1.9	2
126	Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. <i>Rheumatology and Therapy</i> , 2022, 9, 175-189.	2.3	2

#	ARTICLE	IF	CITATIONS
127	SR-A neutralizing antibody: potential drug candidate for ameliorating osteoclastogenesis in rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2022, 207, 297-306.	2.6	2
128	Therapeutic responses and predictors of low-dose interleukin-2 in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
129	Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 553-555.	0.9	1
130	Diagnosis of Autoimmune Diseases: Nanocage-Based Capture-Detection System for the Clinical Diagnosis of Autoimmune Disease (Small 25/2021). <i>Small</i> , 2021, 17, 2170126.	10.0	1
131	Platelet phagocytosis by neutrophils in a patient with antiphospholipid syndrome. <i>Rheumatology & Autoimmunity</i> , 2021, 1, 64-66.	0.8	1
132	Identification of lipopolysaccharide-binding protein as a novel citrullinated autoantigen in rheumatoid arthritis. <i>Rheumatology & Autoimmunity</i> , 0, , .	0.8	1
133	Antibody to peptidoglycan recognition protein (PGLYRP)-2 as a novel biomarker in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 988-994.	0.8	1
134	Scavenger receptor A in immunity and autoimmune diseases: Compelling evidence for targeted therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 461-477.	3.4	1
135	Status of rheumatology practice and professional training courses in rural areas of China-an ILAR project. <i>Clinical Rheumatology</i> , 2017, 36, 213-216.	2.2	0
136	Response to: "Questions on "Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population" by Guo et al" by Regueiro and Gonzalez. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e39-e39.	0.9	0
137	Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 56, .	1.2	0
138	Endoplasmic reticulum stress perpetuated toll-like receptor signalling-mediated inflammation in rheumatoid arthritis via X-box-binding protein-1. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 859-867.	0.8	0
139	Therapeutic responses and predictors of low-dose interleukin-2 in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
140	Serum Antigenome Profiling Reveals Diagnostic Models for Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 884462.	4.8	0